PACB (Pacific Biosciences of California) EPS (Basic): $-0.43 (TTM As of Mar. 2026)

What is Pacific Biosciences of California EPS (Basic)?

Pacific Biosciences of California PACB +11.11% 53 EPS (Basic) is $-0.43 as of Mar. 2026. GuruFocus rates PACB with a GF Score™ of 53/100 and a GF Value™ of $1.62 (Fairly Valued). The stock has 8 warning signs investors should review.

Pacific Biosciences of California's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.03. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.43.

Pacific Biosciences of California's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.43.

Pacific Biosciences of California's EPS without NRI for the three months ended in Mar. 2026 was $-0.12. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.52.

During the past 3 years, the average EPS without NRI Growth Rate was -9.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -26.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was -8.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Pacific Biosciences of California's highest 3-Year average EPS without NRI Growth Rate was 75.40% per year. The lowest was -162.90% per year. And the median was 6.85% per year.

Pacific Biosciences of California (NAS:PACB) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Pacific Biosciences of California EPS (Basic) Related Terms

Pacific Biosciences of California EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Pacific Biosciences of California's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacific Biosciences of California EPS (Basic) Chart

Pacific Biosciences of California Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

-0.89

-1.40

-1.21

-1.13

-1.82

Pacific Biosciences of California Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															-1.44	-0.14	-0.13	-0.13	-0.03

53GF Score

Pacific Biosciences of California Inc PACB

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Pacific Biosciences of California EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Pacific Biosciences of California's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-546.376	-	0)	/	299.959
	=	-1.82

Pacific Biosciences of California's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-8.275	-	0)	/	305.819
	=	-0.03

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.43

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of $-0.43 mean?

Pacific Biosciences of California (PACB) has a EPS (Basic) of $-0.43 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Pacific Biosciences of California and its competitors.

Is Pacific Biosciences of California's EPS (Basic) too high?

Pacific Biosciences of California's current EPS (Basic) is $-0.43. Overall, Pacific Biosciences of California has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Pacific Biosciences of California's EPS (Basic) compare to CATX and LAB?

Pacific Biosciences of California's EPS (Basic) of $-0.43 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Medical Devices & Instruments company?

A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Pacific Biosciences of California and its competitors. Pacific Biosciences of California's current EPS (Basic) is $-0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Pacific Biosciences of California stock overvalued right now?

Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Fairly Valued. The stock's GF Value™ is $1.62, compared to a current price of $1.60 — trading 1.2% below its estimated fair value. The current EPS (Basic) is $-0.43. Pacific Biosciences of California's overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current EPS (Basic) is $-0.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Biosciences of California (PACB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued. The current stock price of $1.60 is trading 1.2% below its estimated GF Value™ of $1.62. GuruFocus considers Pacific Biosciences of California to be Fairly Valued.

Key valuation signals for PACB:

EPS (Basic): $-0.43
GF Value™: $1.62 vs. price of $1.60 (1.2% below fair value)
GF Score™: 53/100 with 8 warning signs

No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacific Biosciences of California Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies CATX LAB KIDS VREX BBNX CTKB CLPT VMD TCMD OFIX ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges P09:Germany

Address 1305 O’Brien Drive, Menlo Park, CA, USA, 94025

Website https://www.pacb.com

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

53GF Score

Get the complete analysis for PACB

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.60

Price

$1.62

GF Value

View PACB Analysis

See EPS (Basic) data for all stocks →